<DOC>
	<DOCNO>NCT00079144</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide fludarabine , work different way stop tumor cell divide stop grow die . Treating person 's lymphocyte laboratory reinfusing may replace immune cell destroy chemotherapy . Vaccines make peptide may make body build immune response kill tumor cell . Giving vaccine Montanide ISA-51 may cause strong immune response kill tumor cell . Interleukin-2 may stimulate person 's lymphocyte kill tumor cell . PURPOSE : This phase II trial study well lymphocyte-depleting nonmyeloablative ( damage bone marrow ) chemotherapy follow autologous lymphocyte infusion , peptide vaccine plus Montanide ISA-51 , interleukin-2 work treat patient metastatic melanoma .</brief_summary>
	<brief_title>Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion , Peptide Vaccine Plus Montanide ISA-51 , Interleukin-2 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical tumor regression patient metastatic melanoma treat lymphocyte-depleting nonmyeloablative preparative chemotherapy regimen follow autologous lymphocyte infusion , ESO-1 peptide vaccination comprise ESO-1:157-165 ( 165V ) Montanide ISA-51 , interleukin-2 . Secondary - Determine survival infused lymphocytes patient treated regimen . - Determine long-term immune status patient treat regimen . OUTLINE : Patients stratify accord type lymphocyte infusion ( ESO-1-reactive tumor-infiltrating lymphocyte [ TIL ] v ESO-1 reactive peripheral blood lymphocyte [ PBL ] ) . - Autologous lymphocyte collection expansion : Autologous PBL TIL collect patient leukapheresis biopsy . The cell sensitize vitro ESO-1:157-165 ( 165V ) melanoma antigen expand . - Lymphocyte-depleting nonmyeloablative preparative chemotherapy : Patients receive lymphocyte-depleting nonmyeloablative preparative chemotherapy comprise cyclophosphamide IV 1 hour day -7 -6 fludarabine IV 15-30 minute day -5 -1 . - Autologous lymphocyte infusion : Autologous PBL TIL reinfused day 0* . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 1 continue blood count recover . - ESO-1 peptide vaccination : Patients receive ESO-1 peptide vaccination comprise ESO-1:157-165 ( 165V ) peptide emulsify Montanide ISA-51 SC day 0*-4 , 11 , 18 , 25 . - Interleukin therapy : Patients receive interleukin-2 IV 15 minute 3 time daily day 0*-4 . NOTE : *Day 0 1-4 day last dose fludarabine . Patients achieve stable disease partial response may receive 1 retreatment course . Patients progressive disease infusion PBL may receive retreatment TIL , available . Patients follow 4-5 week , every 3-4 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 24-74 patient ( 12-37 per stratum ) accrue study within 2-3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic melanoma refractory standard therapy ( include highdose interleukin2 ) Measurable disease HLAA*0201 positive EpsteinBarr virus positive ESO1expressing disease reverse transcription polymerase chain reaction amplify tissue OR presence ESO1 serum antibody PATIENT CHARACTERISTICS : Age 16 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 8.0 g/dL Hepatic Hepatitis B surface antigen negative Hepatitis C antibody negative AST ALT &lt; 3 time upper limit normal Bilirubin ≤ 2.0 mg/dL ( &lt; 3.0 mg/dL patient Gilbert 's syndrome ) No coagulation disorder Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No prior myocardial infarction No major cardiovascular illness stress thallium comparable test No cardiac arrhythmia LVEF ≥ 45 % Normal cardiac stress test require following condition : Prior EKG abnormality Symptoms cardiac ischemia Arrhythmias Age 50 Pulmonary FEV_1 &gt; 60 % predict ( patient prolong history cigarette smoking symptom respiratory dysfunction ) No obstructive restrictive pulmonary disease No major respiratory illness Immunologic HIV negative No active systemic infection No opportunistic infection No major immune system illness No form primary secondary immunodeficiency No known hypersensitivity study agent Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 4 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Prior ESO1based vaccination allow Chemotherapy At least 6 week since prior nitrosoureas recover Endocrine therapy No concurrent systemic steroid therapy Radiotherapy Recovered prior radiotherapy Surgery Not specify Other At least 4 week since prior systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>